Atherogenic lipid profiles and its management in patients with rheumatoid arthritis

por Nurmohamed, Michael T
Publicado 2007

The increased cardiovascular risk in rheumatoid arthritis: when does it start?

por Nurmohamed, Michael T
Publicado 2010

Are biologics more effective than classical disease-modifying antirheumatic drugs?

por Nurmohamed, Michael T, Dijkmans, Ben AC
Publicado 2008

Cardiovascular risk management in rheumatoid arthritis: are we still waiting for the first step?

por Peters, Mike JL, Nurmohamed, Michael T
Publicado 2013

Biologics, cardiovascular effects and cancer

por Damjanov, Nemanja, Nurmohamed, Michael T, Szekanecz, Zoltán
Publicado 2014

Editorial: Comorbidity Burden in Rheumatic Diseases

por Nikiphorou, Elena, Nurmohamed, Michael T., Szekanecz, Zoltan
Publicado 2018

Cardiovascular disease risk in immune-mediated inflammatory diseases: recommendations for clinical practice

por Agca, Rabia, Smulders, Yvo, Nurmohamed, Michael
Publicado 2022

Cardiovascular Disease Risk in Rheumatoid Arthritis Anno 2022

por Dijkshoorn, Bas, Raadsen, Reinder, Nurmohamed, Michael T.
Publicado 2022

Correspondence on “Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatolo...

por van Vollenhoven, Ronald F, Tas, Sander W, Nurmohamed, Michael T
Publicado 2023

Unresolved Questions in Rheumatology: Motion for Debate: The Data Support Evidence-Based Management Recommendations for Cardiovascular Disease in Rheumatoid Arthritis

por Solomon, Daniel H, Peters, Mike J L, Nurmohamed, Michael T, Dixon, Will
Publicado 2013

Multicentric reticulohistiocytosis: a case report

por Farokhi, Azadèh, van Vugt, Richard M., Hoekzema, Rick, Nurmohamed, Michael T.
Publicado 2018

Coagulation in gout: is there a link with disease activity?

por Vedder, Daisy, Gerritsen, Martijn, Meijers, Joost C. M., Nurmohamed, Michael T.
Publicado 2022

Correction to: Coagulation in gout: is there a link with disease activity?

por Vedder, Daisy, Gerritsen, Martijn, Meijers, Joost C. M., Nurmohamed, Michael T.
Publicado 2022

Use of methotrexate therapy is not associated with decreased prevalence of metabolic syndrome

por Raterman, Hennie G, Voskuyl, Alexandre E, Dijkmans, Ben AC, Nurmohamed, Michael T
Publicado 2009

Confounding by Indication Probably Distorts the Relationship between Steroid Use and Cardiovascular Disease in Rheumatoid Arthritis: Results from a Prospective Cohort Study

por van Sijl, Alper M., Boers, Maarten, Voskuyl, Alexandre E., Nurmohamed, Michael T.
Publicado 2014

Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment

por Choy, Ernest, Ganeshalingam, Kandeepan, Semb, Anne Grete, Szekanecz, Zoltán, Nurmohamed, Michael
Publicado 2014

A neutrophil signature is strongly associated with increased cardiovascular risk in gout

por Vedder, Daisy, Gerritsen, Martijn, Nurmohamed, Michael T, van Vollenhoven, Ronald F, Lood, Christian
Publicado 2020

Longer durations of antitumour necrosis factor treatment are associated with reduced risk of cardiovascular events in patients with rheumatoid arthritis

por Nurmohamed, Michael, Bao, Yanjun, Signorovitch, James, Trahey, Alex, Mulani, Parvez, Furst, Daniel E
Publicado 2015

The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review

por Nurmohamed, Michael, Choy, Ernest, Lula, Sadiq, Kola, Blerina, DeMasi, Ryan, Accossato, Paola
Publicado 2018

Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout

por Hansildaar, Romy, Vedder, Daisy, Baniaamam, Milad, Tausche, Anne-Kathrin, Gerritsen, Martijn, Nurmohamed, Michael T
Publicado 2021